Literature DB >> 10644281

Rosiglitazone and hepatic failure.

J Freid, D Everitt, J Boscia.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644281     DOI: 10.7326/0003-4819-132-2-200001180-00015

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

Review 1.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.

Authors:  S H Caldwell; E E Hespenheide; R W von Borstel
Journal:  Dig Dis Sci       Date:  2001-02       Impact factor: 3.199

3.  Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.

Authors:  Herbert L Bonkovsky; Riad Azar; Steven Bird; Gyongyi Szabo; Barbara Banner
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 4.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Rosiglitazone promotes glucose metabolism of GIFT tilapia based on the PI3K/Akt signaling pathway.

Authors:  Dong-Yan Guan; Hui-Wen Sun; Ji-Ting Wang; Zhen Wang; Yang Li; Hao-Jun Han; Xiang Li; Ting-Ting Fang
Journal:  Physiol Rep       Date:  2021-03

6.  Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo.

Authors:  Jah Yeon Choi; Jiheun Ryu; Hyun Jung Kim; Joon Woo Song; Joo Hee Jeon; Dae-Hee Lee; Dong Joo Oh; Dae-Gab Gweon; Wang-Yuhl Oh; Hongki Yoo; Kyeongsoon Park; Jin Won Kim
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.